A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis

Trial Profile

A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Ozanimod (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 26 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 12 Jun 2017 Planned End Date changed from 1 Apr 2017 to 31 Dec 2017.
    • 12 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 31 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top